NYSE: CTLT | Healthcare / Drug Manufacturers / USA |
64.27 | +1.63 | +2.60% | Vol 1.38M | 1Y Perf -41.95% |
Mar 24th, 2023 16:04 DELAYED |
BID | 56.00 | ASK | 77.14 | ||
Open | 62.41 | Previous Close | 64.27 | ||
Pre-Market | - | After-Market | 64.76 | ||
- - | 0.49 0.76% |
Target Price | 81.55 | Analyst Rating | Moderate Buy 1.79 | |
Potential % | 26.89 | Finscreener Ranking | ★★ 45.86 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 54.47 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★ 50.64 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 31.59 | Earnings Rating | Strong Sell | |
Market Cap | 11.57B | Earnings Date | 2nd May 2023 | |
Alpha | 0.01 | Standard Deviation | 0.10 | |
Beta | 1.33 |
Today's Price Range 61.0464.42 | 52W Range 40.69115.34 | 5 Year PE Ratio Range 27.80112.00 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | -4.23% | ||
1 Month | -5.46% | ||
3 Months | 48.26% | ||
6 Months | -15.51% | ||
1 Year | -41.95% | ||
3 Years | 32.98% | ||
5 Years | 63.12% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 9.25 | |||
ROE last 12 Months | 10.34 | |||
ROA (5Y Avg) | 1.68 | |||
ROA last 12 Months | 4.45 | |||
ROC (5Y Avg) | 4.50 | |||
ROC last 12 Months | 6.12 | |||
Return on invested Capital Q | 0.21 | |||
Return on invested Capital Y | 7.52 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 2.90 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
20.30 | ||||
1.82 | ||||
2.40 | ||||
46.70 | ||||
-14.40 | ||||
1.02 | ||||
11.38 | ||||
26.12 | ||||
12.45B | ||||
Forward PE | 20.11 | |||
PEG | 4.14 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.90 | ||||
2.90 | ||||
0.47 | ||||
0.90 | ||||
4.90 | ||||
Leverage Ratio | 2.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
32.60 | ||||
13.10 | ||||
21.30 | ||||
11.30 | ||||
8.92 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.61B | ||||
20.05 | ||||
12.73 | ||||
16.88 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2023 | 0.64 | 0.62 | -3.12 |
Q01 2023 | 0.49 | 0.25 | -48.98 |
Q04 2022 | 1.10 | 1.12 | 1.82 |
Q03 2022 | 0.89 | 1.00 | 12.36 |
Q02 2022 | 0.79 | 0.85 | 7.59 |
Q01 2022 | 0.58 | 0.63 | 8.62 |
Q04 2021 | 1.01 | 1.08 | 6.93 |
Q03 2021 | 0.73 | 0.78 | 6.85 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2022 QR | 0.64 | -15.79 | Negative |
3/2023 QR | 0.85 | -13.27 | Negative |
6/2023 FY | 2.93 | -17.70 | Negative |
6/2024 FY | 3.33 | -20.53 | Negative |
Next Report Date | 2nd May 2023 |
Estimated EPS Next Report | 0.64 |
Estimates Count | 7 |
EPS Growth Next 5 Years % | 4.90 |
Volume Overview | |
---|---|
Volume | 1.38M |
Shares Outstanding | 180.09K |
Shares Float | 140.79M |
Trades Count | 19.62K |
Dollar Volume | 87.20M |
Avg. Volume | 2.06M |
Avg. Weekly Volume | 2.00M |
Avg. Monthly Volume | 1.79M |
Avg. Quarterly Volume | 2.39M |
Catalent Inc. (NYSE: CTLT) stock closed at 64.27 per share at the end of the most recent trading day (a 2.6% change compared to the prior day closing price) with a volume of 1.38M shares and market capitalization of 11.57B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 17300 people. Catalent Inc. CEO is John R. Chiminski.
The one-year performance of Catalent Inc. stock is -41.95%, while year-to-date (YTD) performance is 42.79%. CTLT stock has a five-year performance of 63.12%. Its 52-week range is between 40.69 and 115.335, which gives CTLT stock a 52-week price range ratio of 31.59%
Catalent Inc. currently has a PE ratio of 20.30, a price-to-book (PB) ratio of 1.82, a price-to-sale (PS) ratio of 2.40, a price to cashflow ratio of 46.70, a PEG ratio of 2.32, a ROA of 4.45%, a ROC of 6.12% and a ROE of 10.34%. The company’s profit margin is 8.92%, its EBITDA margin is 21.30%, and its revenue ttm is $3.61 Billion , which makes it $20.05 revenue per share.
Of the last four earnings reports from Catalent Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.64 for the next earnings report. Catalent Inc.’s next earnings report date is 02nd May 2023.
The consensus rating of Wall Street analysts for Catalent Inc. is Moderate Buy (1.79), with a target price of $81.55, which is +26.89% compared to the current price. The earnings rating for Catalent Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Catalent Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Catalent Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.67, ATR14 : 2.99, CCI20 : -172.55, Chaikin Money Flow : -0.05, MACD : 0.04, Money Flow Index : 32.81, ROC : -7.91, RSI : 45.08, STOCH (14,3) : 29.15, STOCH RSI : 0.22, UO : 44.19, Williams %R : -70.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Catalent Inc. in the last 12-months were: Alessandro Maselli (Sold 816 shares of value $87 230 ), Aristippos Gennadios (Sold 806 shares of value $86 161 ), John R. Chiminski (Sold 9 691 shares of value $1 035 967 ), Jonathan Arnold (Sold 188 shares of value $20 097 ), Kay A Schmidt (Sold 323 shares of value $34 529 ), Lorenzo Carletti (Sold 631 shares of value $67 454 ), Manja Boerman (Sold 780 shares of value $40 326 ), Mario Gargiulo (Sold 2 174 shares of value $232 327 ), Michael A. Riley (Sold 2 491 shares of value $259 238 ), Michael J. Grippo (Sold 797 shares of value $85 498 ), Ricardo Pravda (Sold 427 shares of value $45 646 ), Ricky Hopson (Sold 10 000 shares of value $918 290 ), Scott Gunther (Sold 2 483 shares of value $261 098 ), Steven L. Fasman (Sold 15 092 shares of value $1 615 039 ), Thomas P. Castellano (Sold 347 shares of value $37 094 ), Thomas W. Hawkeswood (Sold 930 shares of value $72 038 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Moderate Buy | Moderate Buy | Moderate Buy |
Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.
CEO: John R. Chiminski
Telephone: +1 732 537-6200
Address: 14 Schoolhouse Road, Somerset 08873, NJ, US
Number of employees: 17 300
Wed, 08 Feb 2023 13:15 GMT Catalent (CTLT) Gets a Buy from Jefferies
- TipRanks. All rights reserved.Sat, 04 Feb 2023 22:09 GMT Danaher has expressed takeover interest in Catalent, Bloomberg says
- TipRanks. All rights reserved.Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.